Maze Therapeutics reported positive mid-stage efficacy for MZE829, its oral APOL1 inhibitor for broad APOL1-mediated kidney disease (AMKD), setting up a direct race toward a pivotal program. In its Phase 2 Horizon trial, Maze said MZE829 delivered a clinically meaningful reduction in urine protein measured by average urinary albumin-to-creatinine ratio (uACR) of 35.6% at week 12 across 12 efficacy-evaluable patients. Subgroup results were also stronger in focal segmental glomerulosclerosis (FSGS) patients, with a 61.8% reduction, and in AMKD patients without diabetes, with a 48.6% reduction. Maze said it will continue enrollment and plans regulator engagement to move toward a pivotal trial for this genetically driven indication where no approved therapies specifically target AMKD. The company also flagged that full Phase 2 results will be presented at an upcoming medical meeting. Investors and analysts immediately compared Maze’s program to Vertex Pharmaceuticals’ AMKD approach, given the shared genetic rationale and proteinuria endpoints.